ArticleSmall science2025
A Rapid Assessment Approach for Skin Stratum-Targeted Drug Delivery Systems Using Mass Spectrometry Imaging and Spatial Clustering.
Article in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel mass spectrometry imaging (MSI)-based concept that enables rapid visualization and evaluation of active pharmaceutical ingredient (API) distribution across skin layers following dermal delivery is presented. This approach integrates desorption electrospray ionization MSI with a newly developed automated computational tool (access provided) that efficiently processes MSI data, isolates skin tissue signals from background interference, and segments the tissue into precise layers. The tool facilitates detailed and rapid assessment of API localization within skin strata in under 10 min per skin specimen. To validate this method, three nanoscale dermal drug delivery systems (DDSs) for the antifungal terbinafine that target distinct skin strata-ethosomes, transethosomes, and microemulsion-are designed and characterized. API permeation in human and porcine skin is evaluated using both manual and automated workflows. The integrated approach demonstrates superior accuracy in skin distribution analysis, a substantial reduction in processing time, and improved efficiency in signal-tissue overlay. Comparative analysis of the DDSs reveals marked differences in drug permeation depth and localization, with transethosomes showing the highest potential for deeper dermal delivery. This method not only provides a powerful tool for DDS evaluation but also enables detailed kinetic studies, offering insights into drug permeation dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.